:::

詳目顯示

回上一頁
題名:遺傳檢測與諮詢的倫理議題與執業準則--罹病傾向之遺傳檢測:以BRCA檢驗為例
書刊名:醫學教育
作者:蔡甫昌朱怡康黃天祥
作者(外文):Tsai, Daniel Fu-ChangChu, I-KangHuang, Tien-Shang
出版日期:2007
卷期:11:1
頁次:頁69-88
主題關鍵詞:遺傳檢測遺傳諮詢倫理準則Genetic testingGenetic counselingBRCAEthics guideline
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(2) 博士論文(1) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:2
  • 共同引用共同引用:0
  • 點閱點閱:50
期刊論文
1.Feuer, E. J.、Wun, L. M.、Boring, C. C.(1993)。The lifetime risk of developing breast cancer。J Natl Cancer Inst,85,892-897。  new window
2.Robson, M. E.(2002)。Clinical considerations in the management of individuals at risk for hereditary breast and ovarian cancer。Cancer Control,9,457-465。  new window
3.Markman, M.(2004)。Genetic discrimination arising from cancer risk assessments: a societal dilemma。Cleve Clin J Med,71,12-18。  new window
4.蘇怡寧(20020900)。乳癌之BRCA1/BRCA2之基因分析。臺灣醫學,6(5),706-713。  延伸查詢new window
5.Schrag, D.、Kuntz, K. M.、Garber, J.(2000)。Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 and BRCA2 mutations。J Am Med Assoc,283,617-624。  new window
6.Burke, W.、Daly, M.、Garber, J.(1997)。Recommendations for follow-up care of individuals with an inherited predisposition to cancer, II: BRCA1 and BRCA2 cancer genetics studies consortium。J Am Med Assoc,277,997-1003。  new window
7.Early Breast Cancer Trialists' Collaborative Group(1998)。Tamoxifen for early breast cancer: an overview of the randomised trial。Lancet,351,1451-1467。  new window
8.Fisher, B.、Costantino, J. P.、Wickerham, D. L.(1998)。Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-l study。J Natl Cancer Inst,90,1371-1388。  new window
9.(1987)。The cancer and steroid hormone study of the centers for disease control and the National Institute of Child and Human Development: the reduction in risk of ovarian cancer associated with oral contraceptive use。N Engl J Med,316,650-655。  new window
10.NIH consensus conference, Ovarian cancer(1995)。Screening, treatment and follow-up: NIH consensus development panel on ovarian cancer。J Am Med Assoc,273,491-497。  new window
11.Lerman, C.、Narod, S.、Schulman, K.(1996)。BRCA1 testing in families with hereditary breast-ovarian cancer: a prospective study of patient decision making and outcomes。J Am Med Assoc,275,1885-1892。  new window
12.Meijers-Heijboer, H.、van Geel, B.、van Putten, W. L. J.(2001)。Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation。N Engl J Med,345,159-164。  new window
13.Hartmann, L. C.、Schaid, D.、Sellers, T.(2000)。Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutations carriers。Proc Am Assoc Cane Res,41,222-223。  new window
14.Ursin, G.、Li, C.、Pike, M. C.(2000)。Should women with a family history of breast cancer avoid use of oral contraceptives?。Epidemiology,11,615-616。  new window
15.Weber, B. L.、Punzalan, C.、Eisen, A.(2000)。Ovarian cancer risk reduction after bilateral prophylactic oophorectomy (BPO) in BRCA1 and BRCA2 mutation carriers。Am J Hum Genet,67(Suppl. 2)。  new window
16.American Society of Clinical Oncology(2003)。American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility。J Clin Oncol,21,2397-2406。  new window
17.de Wert, G.(1996)。Ethics of predictive DNA-testing for hereditary breast and ovarian cancer。Obstet Gynecol,87,306-309。  new window
18.McKinnon, W. C.、Baty, B. J.、Bennett, R. L.(1997)。Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors。J Am Med Assoc,278,1217-1220。  new window
19.The American Society of Human Genetics(1998)。Professional disclosure of familial genetic information。Am J Hum Genet,62,474-483。  new window
20.The American College of Medical Genetics、The American Society of Human Genetics(1995)。ASHG/ACMG Report: Points to Consider: Ethical, Legal, and Psychosocial Implications of Genetic Testing in Children and Adolescents。Am. J. Hum. Genet.,57(5),1233-1241。  new window
21.European Society of Human Genetics(2003)。Provision of genetic services in Europe: current practices and issues。European Journal of Human Genetics,11,900-902。  new window
22.Cobben, J. M.、Bröcker-Vriends, A. H.、Leschot, N. J.(2002)。Prenatal diagnosis for hereditary predisposition to mammary and ovarian carcinoma-defining a position。Ned Tijdschr Geneeskd,146,1461-1465。  new window
23.European Society of Human Genetics(2000)。Genetic Information and Testing in Insurance and Employment: Technical, Social and Ethical Issues。European journal of human genetics,11(12),909-910。  new window
研究報告
1.Advisory Committee on Genetic Testing(1998)。Report on Genetic Testing for Late Onset Disorders。London:Health Department of United Kingdom。  new window
2.行政院衛生署國民健康局。衛生署癌症登記年報。  延伸查詢new window
3.Council on Scientific Affairs(1999)。Mammographic Screening for Asymptomatic Women: Report。Chicago, Illinois:American Medical Association。  new window
4.Wertz, D. C.、Fletcher, J. C.、Berg, K.(2003)。Review of Ethical Issues in Medical Genetics: Report of Consultants to WHO。Geneva:World Health Organization。  new window
5.Clinical Genetics Society(1994)。The Genetic Testing of Children: Report of a Working Party of the Clinical Genetics Society。  new window
6.Advisory Committee on Genetic Testing(2000)。Prenatal Genetic Testing: Report for Consultation。  new window
圖書
1.de Wert, G.、ter Meulen, R.、Mordacci, R.(2003)。Ethics and Genetics: A Workbook for Practitioners and Students。NY:Berghahn Books。  new window
2.The President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Biobehavioral Research(1998)。Screening and Counseling for Genetic Conditions: The Ethical, Social, and Legal Implications of Genetics Screening, Counseling and Education Programs。Washington, DC:US Government Publishing Office。  new window
3.Institute of Medicine Committee on Assessing Genetic Risks(1994)。Assessing Genetic Risks: Implications for Health and Social Policy。Washington, DC:National Academy Press。  new window
4.World Health Organization(1997)。Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetic Service。Geneva:World Health Organization。  new window
其他
1.Ethical Issues in Genetic Testing for BRCA1 and BRCA2,http://www.ama-assn.org/cmeselec/ethics。  new window
2.Ethical Issues in Genetic Testing for BRCA1 and BRCA2. Post-Test Confidentiality,http://www.ama-assn.org/cmeselec/ethics/60-testresults/07.htm。  new window
3.Association of British Insurers(1999)。Genetic Testing Code of Practice。  new window
4.The America College of Medical Genetics, the New York State Department of Health(1999)。Genetic Susceptibility to Breast and Ovarian Cancer: Assessment, Counseling and Testing Guidelines,http://www.health.state.ny.us/nysdoh/cancer/obcancer/pp24-27.htm。  new window
5.American Cancer Society(1997)。Recommendations for Early Breast Cancer Detection。  new window
6.Human Genetics Society of Australasia(1999)。Guidelines for the Practice of Genetic Counseling。  new window
7.British Medical Association(1991)。Confidentiality and Disclosure of Health Information: Examples of Disclosure in the Public Interest,http://www.bma.org.uk/ap.nsf/Content/Confidentialitydisclosure-examplespublic。  new window
8.Ethical Issues in Genetic Testing for BRCA1 and BRCA2. Genetic Discrimination,http://www.ama-assn.org/cmeselec/ethics/40_nondir/10.htm。  new window
圖書論文
1.The International Federation of Gynecology and Obstetrics(2003)。Ethical issues concerning prenatal diagnosis of disease in the conceptus, 1991。Recommendations on Ethical Issues in Obstetrics and Gynecology by the FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health。London:FIGO。  new window
2.The International Federation of Gynecology and Obstetrics(2003)。Ethical aspects of termination of pregnancy following prenatal diagnosis, 1991。Recommendations on Ethical Issues in Obstetrics and Gynecology by the FIGO Committee for the Ethical Aspects of Human Reproduction and Women's Health。London:FIGO。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
QR Code
QRCODE